GROUP EDUCATIONAL OUTREACH
Fall/Winter 2024
Request a 1-hour Presentation at your medical practice or hospital
2022 CDC Opioid Prescribing Guideline
Using case-based learning, this educational outreach presentation will review recommendations for opioid prescribing for acute and chronic pain. The 2022 Guideline builds upon and clarifies recommendations published in 2016. At the end of the presentation, learners should be able to:
– Recall at least four of the Guideline’s 12 Recommendations.
– List two strategies for managing acute pain.
– Implement one recommendation for patients on long-term opioid therapy (LTOT).
slides handout
The Hanley Center for Health Leadership and Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Hanley Center for Health Leadership and Education and the Maine Independent Clinical Information Service (MICIS). The Hanley Center for Health Leadership and Education is accredited by the Maine Medical Association Committee on Continuing Medical Education and Accreditation to provide continuing medical education for physicians.
This activity qualifies for 1 credit of the 3 CME credit requirement for opioid medication education found in P.L. 2015, Chapter 488, Maine’s legislation to address the opioid drug crisis.
Diabetes Update Focusing on GLP-1s and SGLT-2s
About one in ten Americans have diabetes with type 2 accounting for 90-95%. The glucagon-like peptide (GLP-1) agonists and sodium-glucose transport protein 2 (SGLT-2) inhibitors are two of the more recently developed classes of diabetes drugs with the first drug approved in each class in 2005 and 2013, respectively. This program will focus on these drug classes to include how they work, risks and benefits, other indications and cost. Other nonpharmacological aspects of diabetes management will be reviewed including diabetes prevention strategies, individualized glucose recommendations and comprehensive diabetes care recommendations. The overlap among diabetes and other metabolic diseases (obesity, hypertension, cardiovascular disease, hyperlipidemia, kidney disease) will be woven into the various sections. The GLP-1s and SGLT-2s have newer indications including weight loss and heart failure treatment, even without diabetes, Prescribers will benefit from a comprehensive, nonbiased review of these drug classes.
– Analyze strategies for diabetes prevention
– Investigate the pharmacology of the diabetes drug classes: GLPS-1s and SGLT-2s
– Formulate a framework for comprehensive diabetes care
slides GLP-1s SGLT-2s
The Maine Medical Education Trust designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Maine Medical Education Trust and the Maine Independent Clinical Information Service (MICIS). The Maine Medical Education Trust is accredited by the Maine Medical Association Committee on Continuing Medical Education and Accreditation to provide continuing medical education for physicians.
ACADEMIC DETAILING 2024-2025
Request a 1-hour Individual Session with an Academic Detailer
A MICIS Academic Detailing session is an individualized one-on-one conversation with a specially trained physician. Open to any prescriber in Maine.
Simplified Treatment of Hepatitis C in Primary Care Settings
Discuss diagnostic testing and guidelines for primary care based treatment of Hepatitis C.
Diabetes Update Focusing on GLP-1s and SGLT-2s
Review the properties, risks and benefits of these medications approved for diabetes and obesity.
Opioid Prescribing Topics – 2 topics in 2024
Diagnosing and Treating Opioid Use Disorder (OUD)
Learning Objectives:
– Review the diagnostic criteria for opioid use disorder and other use disorders.
– Compare the three medications available to treat OUD.
– Discuss initiating and dosing buprenorphine formulations.
– Plan to incorporate Harm Reduction strategies for OUD treatment into practice.
Maine Controlled Substance Prescribing: 2024 Update
Learning Objectives:
– Review the “Universal Precautions” of prescribing controlled substances.
– Discuss Maine-specific laws and rules pertaining to prescribing opioids.
– Evaluate risks and benefits of legacy patients who are prescribed chronic opioids and benzodiazepines.
– Access the 2022 CDC Opioid Prescribing Guideline’s recommendations.
The Maine Medical Education Trust designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Maine Medical Education Trust and the Maine Independent Clinical Information Service (MICIS). The Maine Medical Education Trust is accredited by the Maine Medical Association Committee on Continuing Medical Education and Accreditation to provide continuing medical education for physicians.